Brookline Capital Management Downgrades Daré Bioscience (NASDAQ:DARE) to Hold

Daré Bioscience (NASDAQ:DARE) was downgraded by Brookline Capital Management from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday, Marketbeat reports.

Several other research analysts have also weighed in on DARE. HC Wainwright reissued a “buy” rating and set a $6.00 price objective on shares of Daré Bioscience in a report on Monday, April 1st. Dawson James lowered shares of Daré Bioscience from a “buy” rating to a “neutral” rating in a report on Tuesday, January 30th.

Daré Bioscience Price Performance

Shares of DARE stock opened at $0.30 on Wednesday. The firm has a market cap of $29.68 million, a P/E ratio of -0.87 and a beta of 1.16. Daré Bioscience has a 1-year low of $0.27 and a 1-year high of $1.10. The firm has a fifty day moving average of $0.46 and a two-hundred day moving average of $0.40.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Bank of New York Mellon Corp acquired a new position in shares of Daré Bioscience in the 1st quarter valued at about $34,000. Citigroup Inc. acquired a new position in shares of Daré Bioscience in the 1st quarter valued at about $40,000. Bank of America Corp DE bought a new stake in Daré Bioscience in the 1st quarter valued at about $44,000. Morgan Stanley lifted its position in Daré Bioscience by 283.4% in the 4th quarter. Morgan Stanley now owns 67,646 shares of the biotechnology company’s stock valued at $56,000 after purchasing an additional 50,000 shares during the last quarter. Finally, UBS Group AG lifted its position in Daré Bioscience by 11,198.4% in the 3rd quarter. UBS Group AG now owns 56,492 shares of the biotechnology company’s stock valued at $57,000 after purchasing an additional 55,992 shares during the last quarter. 6.70% of the stock is owned by institutional investors and hedge funds.

About Daré Bioscience

Daré Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health.